Annual General Meeting 06

Oxford Biomedica PLC
04 May 2006



FOR IMMEDIATE RELEASE                                                 4 MAY 2006



                  OXFORD BIOMEDICA ANNUAL GENERAL MEETING 2006

Oxford, UK - 4 May 2006: Oxford BioMedica (LSE: OXB), the leading gene therapy
company, announced today that all resolutions were duly passed at its Annual
General Meeting, held today in London.

                                     -Ends-




For further information, please contact:
Oxford BioMedica plc:                                    Tel: [phone]
                                                                 
Professor Alan Kingsman, Chief Executive
City/Financial Enquiries:                                Tel: [phone]
                                                                       
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan
Communications
Scientific/Trade Press Enquiries:                        Tel: [phone]
                                                                       
Katja Stout/ Gemma Bradley
Northbank Communications



Notes to editors


1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange.


Oxford BioMedica has core expertise in gene delivery, as well as in-house
clinical, regulatory and manufacturing know-how. In oncology, the pipeline
includes two candidates in multiple Phase II trials, and a preclinical targeted
antibody therapy in collaboration with Wyeth. A Phase III trial in renal cancer
with TroVax, the lead cancer immunotherapy candidate, is planned for the second
half of 2006. In neurotherapy, the Company's lead product is a gene therapy for
Parkinson's disease, which is expected to enter clinical development in 2006,
and four further preclinical candidates. The Company is underpinned by over 80
patent families, which represent one of the broadest patent estates in the
field.


The Company has a staff of approximately 70 split between its main facilities in
Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.
Oxford BioMedica has corporate collaborations with Wyeth, Intervet,
Sigma-Aldrich, Viragen, MolMed, VIRxSYS and Kiadis; and has licensed technology
to a number of companies including Merck & Co, Biogen Idec and Pfizer.

Further information is available at www.oxfordbiomedica.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange